Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy.Nat Rev Clin Oncol. 2015; 12: 335-343
- Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.Ann Oncol. 2019; 30: 1541-1557
- National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (Breast Cancer) Version 5.2021, June 28, 2021. Version 4.2021 — April 28, 2021.(Available at:) (Accessed July 05, 2021)
- Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox.Lancet Oncol. 2021; 22: e18-e28
- Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes.Ann Surg Oncol. 2018; 25: 2241-2248
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.Lancet Oncol. 2018; 19: 27-39
- Selecting node-positive patients for axillary downstaging with neoadjuvant chemotherapy.Ann Surg Oncol. 2020; 27: 4515-4522
- Locoregional control according to breast cancer subtype and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast-conserving therapy.Ann Surg Oncol. 2016; 23: 749-756
- How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.Ann Surg Oncol. 2016; 23: 3467-3474
- Sentinel Node Biopsy alone or with Axillary Dissection in Breast Cancer Patients after Primary Chemotherapy: Long-term Results of a Prospective Interventional Study.Ann Surg. 2020; https://doi.org/10.1097/SLA.0000000000004562
- Oncologic Outcomes of Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer.Ann Surg Oncol. 2020; 27: 4795-4801
- Oncologic Safety of Sentinel Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy for Breast Cancer.Ann Surg Oncol. 2021; 28: 2621-2629
- Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event.JAMA Oncol. 2021; 7: 1851-1855
- Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery.(Available at:) (Accessed July 05, 2021)
- Eliminating Surgery After Systemic Therapy in Treating Patients With HER2 Positive or Triple Negative Breast Cancer.(Available at:) (Accessed July 05, 2021)
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.N Engl J Med. 2017; 376: 2147-2159
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.N Engl J Med. 2019; 380: 617-628
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.N Engl J Med. 2021; 384: 2394-2405
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.Lancet. 2014; 384: 164-172
- Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.J Clin Oncol. 1997; 15: 2483-2493
- Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).Ann Surg. 2015; 262 ([discussion: 438–9]): 434-439
- Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).Breast Cancer Res Treat. 2016; 160: 297-304
- How Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery?.Ann Surg Oncol. 2021; 28: 287-294
- Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.J Clin Oncol. 1998; 16: 2672-2685
- Perspectives on preoperative systemic treatment and breast conservative surgery: One step forward or two steps back?.Breast. 2018; 41: 133-135
- Neoadjuvant chemotherapy for early breast cancer.Lancet Oncol. 2018; 19: e128
- Neoadjuvant chemotherapy for early breast cancer.Lancet Oncol. 2018; 19: e129
- Is Locoregional Recurrence Higher Among Patients Who Downstage to Breast Conservation After Neoadjuvant Chemotherapy?.Ann Surg Oncol. 2021; 28: S49-S50
- Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study.J Clin Oncol. 2009; 27: 726-732
- Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients.Ann Surg. 2009; 250: 558-566
- Axillary Nodal Management Following Neoadjuvant Chemotherapy: A Review.JAMA Oncol. 2017; 3: 549-555
- Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.J Clin Oncol. 2015; 33: 258-264
- Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.JAMA. 2013; 310: 1455-1461
- Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.Breast Cancer Res Treat. 2019; 173: 343-352
- Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.Lancet Oncol. 2013; 14: 609-618
- Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance).Ann Surg. 2015; 261: 547-552
- CUSTOMIZING LOCAL AND SYSTEMIC THERAPIES FOR WOMEN WITH EARLY BREAST CANCER: The St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.Ann Oncol. 2021; 32: 1216-1235
- Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2019; 30: 1674
- Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?.Ann Surg Oncol. 2018; 25: 1488-1494
- Is residual nodal disease at axillary dissection associated with tumor subtype in patients with low volume sentinel node metastasis after neoadjuvant chemotherapy?.Ann Surg Oncol. 2021; 28: 6044-6050
- Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer.Ann Surg Oncol. 2019; 26: 3502-3509
- Predicting non-sentinel lymph node metastases in patients with a positive sentinel lymph node after neoadjuvant chemotherapy.Ann Surg Oncol. 2018; 25: 2867-2874
- Decreasing use of axillary dissection in node-positive breast cancer patients treated with neoadjuvant chemotherapy.Ann Surg Oncol. 2018; 25: 2596-2602
- Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype.Eur J Surg Oncol. 2019; 45: 969-975
- Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up.Eur J Surg Oncol. 2021; 47: 804-812
- Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.Ann Surg. 2016; 264: 413-420
- Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.J Clin Oncol. 2013; 31: 3083-3090
- Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century.Breast Cancer Res Treat. 2009; 117: 319-324
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.J Clin Oncol. 2021; 39: 1448-1457
- Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.Eur J Cancer. 2012; 48: 3342-3354
- Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy.Breast Cancer Res Treat. 2018; 170: 559-567
- Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients.Breast Cancer Res Treat. 2017; 163: 83-91
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.Lancet Oncol. 2012; 13: 25-32
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.Lancet Oncol. 2014; 15: 747-756
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.JAMA Oncol. 2020; 6: 676-684
- Nonoperative Management for Invasive Breast Cancer After Neoadjuvant Systemic Therapy: Conceptual Basis and Fundamental International Feasibility Clinical Trials.Ann Surg Oncol. 2017; 24: 2855-2862
- De-escalation of breast and axillary surgery in exceptional responders to neoadjuvant systemic treatment.Lancet Oncol. 2021; 22: 435-436
- Is radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy?.Int J Radiat Oncol Biol Phys. 2011; 79: 1452-1459
- Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials.Breast Cancer Res. 2016; 18: 28
- Imaging Neoadjuvant Therapy Response in Breast Cancer.Radiology. 2017; 285: 358-375
- MRI and PET/CT for evaluation of the pathological response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis.Breast. 2018; 40: 106-115
- Multimodality Imaging for Evaluating Response to Neoadjuvant Chemotherapy in Breast Cancer.AJR Am J Roentgenol. 2017; 208: 290-299
- MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer.J Am Coll Surg. 2017; 225: 740-746
- Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study.Ann Surg Oncol. 2021; 28: 3243-3253
- Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03.Ann Surg. 2022; 275: 576-581
- Abstract GS5-05: Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery.(Available at:) (Accessed July 10, 2021)
- Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer.JAMA Surg. 2020; 155: e204103
- Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.J Clin Oncol. 2012; 30: 3960-3966
- Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.Trials. 2018; 19: 667
- American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome.J Natl Cancer Inst. 2005; 97: 1137-1142
- Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.J Clin Oncol. 2008; 26: 1275-1281
- Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.J Clin Oncol. 2017; 35: 1049-1060
- Escalating and De-escalating Therapy for Early-Stage HER2-Positive Breast Cancer.Am Soc Clin Oncol Educ Book. 2020; 40: 1-11
- The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer.Ann Surg Oncol. 2021; 28: 2111-2119
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.Lancet. 2010; 375: 377-384
- 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.Lancet Oncol. 2016; 17: 791-800
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).Ann Oncol. 2013; 24: 2278-2284
- Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.Lancet Oncol. 2013; 14: 1183-1192
- Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.J Clin Oncol. 2016; 34: 542-549
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.Lancet Oncol. 2014; 15: 1137-1146
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.N Engl J Med. 2017; 377: 122-131
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy.(Available at:) (Accessed July 05, 2021)
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.Lancet. 2019; 393: 1440-1452
- Neoadjuvant dose-dense chemotherapy for locally advanced breast cancer: a meta-analysis of published studies.Anticancer Drugs. 2016; 27: 702-708
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.Nat Med. 2018; 24: 628-637
- Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).J Clin Oncol. 2015; 33: 13-21
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.Lancet Oncol. 2018; 19: 497-509
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.N Engl J Med. 2018; 379: 2108-2121
- Pembrolizumab for Early Triple-Negative Breast Cancer.N Engl J Med. 2020; 382: 810-821
- A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.Ann Oncol. 2019; 30: 1279-1288
- Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. 2019.(Available at:) (Accessed July 05, 2021)
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.Lancet. 2020; 396: 1090-1100
- VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab D chemotherapy vs. placebo D chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early- stage TNBC.Ann Oncol. 2019; 30: v851-v934
- Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.N Engl J Med. 2017; 377: 1792-1793
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.N Engl J Med. 2018; 379: 753-763
- Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study. J Clin Oncol 2021.(Available at:) (Accessed July 09, 2021)
- Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.N Engl J Med. 2019; 380: 2395-2405
- 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.Lancet Oncol. 2021; 22: 476-488
- Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust.Ann Oncol. 2021; 32: 1077-1082
- Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.JAMA Oncol. 2016; 2: 1477-1486
- How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery?.Ann Surg Oncol. 2020; 27: 4702-4710
- Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder).Cancer Res. 2021; : 81
- A Study of the Use of Sentinel Lymph Node Biopsy in Women With Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Breast Conservation Therapy.(Available at:) (Accessed July 22, 2019)
- Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer.Clin Cancer Res. 2021; 27: 2584-2591
- Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.JAMA Oncol. 2020; 6: 1410-1415
- Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery.(Available at:) (Accessed July 10, 2021)
- Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.JAMA Oncol. 2017; 3: 1378-1385
Article info
Publication history
Published online: April 07, 2022
Footnotes
Conflict of Interest Disclosure: All authors have no conflicts of interest to disclose.
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
